top of page

LATEST FROM NCF

Make a Difference

Donate today and help us  provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers.

Soft Blue Sky

MAKE A DIFFERENCE

Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers.

SPOTLIGHT ON INDIVIDUAL CLINICAL TRIALS

DAREON®-NEC-1: Obrixtamig Plus Chemotherapy vs Standard Chemotherapy in Advanced epNEC • Dr. Grewal
19:41
(STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET • ClinicalTrials.gov ID: NCT06943755
06:46
Tarlatamab in DLL3-Expressing Tumors Including NEN • ClinicalTrials.gov: NCT06788938 • Dr. Goldman
14:15
A Study of ZL-1310 in Participants With Selected Solid Tumors • ClinicalTrials.gov ID: NCT06885281
13:57
(CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen•NCT07087054
06:54
Study of 225Ac-ABD147 to Establish Optimal Dose • ClinicalTrials.gov: NCT06736418 • Dr. Chauhan
08:57
May 19, 2025: Dr. Aman Chauhan discusses the DAREON-5 & DAREON-7 Studies
12:34
SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated NEC or Well-Differentiated High-Grade NET
16:57

RECENT EDUCATIONAL EVENTS FOR PATIENTS 

LIVE with Mintallah Haider, MD!
01:00:19
'Luncheon With The Experts' with Aman Chauhan, MD!
01:02:28
'Luncheon With The Experts' with J. Randolph Hecht, MD!
01:07:31
LIVE with Jonathan Strosberg, MD!
01:01:16
LIVE with Jason S. Starr, DO!
01:01:09
LIVE with Jaydira Del Rivero, MD!
01:02:33
Dr. Boris G. Naraev • Luncheon With The Experts • 2026
51:48

LATEST PODCAST EPISODES 

RESOURCES & INFORMATION FOR YOU

ABOUT THE NEUROENDOCRINE CANCER FOUNDATION

Why Our Work Matters

​

The Neuroendocrine Cancer Foundation (NCF) exists to ensure no one faces neuroendocrine cancer alone. We support patients, caregivers, and clinicians through education, connection, and compassionate resources.

​

Educate

​

Support

​

Connect 

​​​

Inform 

Soft Blue Sky

​Neuroendocrine cancer (also known as NET, neuroendocrine tumor, neuroendocrine neoplasm, carcinoid, or neuroendocrine carcinoma) is a rare/uncommon and complex disease.

​

  • 8 in 100,000 people in the U.S. are diagnosed each year

  • Symptoms vary widely and are often misunderstood

  • Diagnosis can take several years

  • Many patients do not meet someone else living with neuroendocrine cancer until they find NCF

​

Patients often struggle to find specialists, up-to-date treatment guidance, and emotional support. NCF fills those gaps by offering what patients need most: credible education, expert access, and a community that understands.

​​

NCF provides these life-changing resources — ensuring patients and families receive guidance when it matters most.

Quotation Marks

I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community.

— NET Patient

NEUROENDOCRINE CANCER FOUNDATION
 
Mailing Address:
PO BOX 370466
DENVER, CO 80237

info@ncf.net
​
  • Facebook
  • Instagram
  • X
  • Youtube
  • LinkedIn

© 2025 by Neuroendocrine Cancer Foundation

bottom of page